Table 2 Locoregional and systemic therapies after brain metastasis diagnosis
From: Temporal evolution of breast cancer brain metastases treatments and outcomes
Group A (2000-2007) N = 241 (%) | Group B (2008-2014) N = 323 (%) | Group C (2015-2022) N = 215 (%) | p value | |
|---|---|---|---|---|
Neurosurgery | ||||
Yes | 28 (11.6) | 36 (11.1) | 32 (14.9) | 0.401 |
No | 213 (88.4) | 287 (88.9) | 183 (85.1) | |
Any type of radiotherapy | ||||
Yes | 198 (82.2) | 230 (71.2) | 144 (67.0) | 0.001 |
No | 43 (17.8) | 93 (28.8) | 67 (31.2) | |
Missing | 0 (0.0) | 0 (0.0) | 4 (1.8) | |
WBRT | ||||
Yes | 191 (79.3) | 187 (57.9) | 93 (43.2) | <0.001 |
No | 50 (20.7) | 134 (41.5) | 118 (54.9) | |
Missing | 0 (0.0) | 2 (0.6) | 4 (1.9) | |
Stereotactic radiotherapy | ||||
Yes | 10 (4.1) | 24 (7.4) | 69 (32.1) | <0.001 |
No | 231 (95.9) | 297 (92.0) | 142 (66.0) | |
Missing | 0 (0.0) | 2 (0.6) | 4 (1.9) | |
Chemotherapy | ||||
Yes | 163 (67.6) | 205 (63.5) | 133 (61.9) | 0.463 |
No | 77 (32.0) | 116 (35.9) | 79 (36.7) | |
Missing | 1 (0.4) | 2 (0.6) | 3 (1.4) | |
Endocrine therapy* | ||||
Yes | 25 (20.8) | 57 (32.2) | 51 (37.5) | 0.056 |
No | 81 (67.5) | 115 (65.0) | 83 (61.0) | |
Missing | 14 (11.7) | 5 (2.8) | 2 (1.5) | |
Anti-HER2 therapy** | ||||
Yes | 68 (64.8) | 105 (74.5) | 71 (82.5) | 0.011 |
No | 37 (35.2) | 33 (23.4) | 14 (16.3) | |
Missing | 0 (0.0) | 3 (2.1) | 1 (1.2) | |
Number anti-HER2 therapies**, median (IQR) | 1 (0-1) | 1 (1-2) | 1 (1-2) | 0.002*** |
Number anti-HER2 therapies** | 0.002 | |||
0 | 37 (35.2) | 33 (23.4) | 14 (16.3) | |
1 | 37 (35.2) | 41 (29.1) | 38 (44.2) | |
2 | 11 (10.5) | 33 (23.4) | 19 (22.1) | |
≥3 | 11 (10.5) | 30 (21.3) | 14 (16.3) | |
Missing | 9 (8.6) | 4 (2.8) | 1 (1.1) |
